Resona Asset Management Co. Ltd. Acquires Shares of 185,539 Edwards Lifesciences Co. (NYSE:EW)

Resona Asset Management Co. Ltd. acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 185,539 shares of the medical research company’s stock, valued at approximately $13,779,000.

Several other institutional investors have also recently made changes to their positions in EW. Crowley Wealth Management Inc. bought a new stake in Edwards Lifesciences during the fourth quarter worth $26,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $30,000. Roble Belko & Company Inc bought a new position in Edwards Lifesciences during the fourth quarter valued at about $46,000. Finally, Catalyst Capital Advisors LLC purchased a new stake in Edwards Lifesciences during the fourth quarter worth about $54,000. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 62,553 shares of company stock worth $4,513,064. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Down 4.9 %

EW stock opened at $69.39 on Monday. The company’s 50 day moving average is $71.74 and its 200 day moving average is $70.66. The stock has a market cap of $40.79 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Canaccord Genuity Group raised their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Evercore ISI dropped their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Citigroup increased their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Piper Sandler boosted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.